

EPIX MEDICAL INC
Form 8-K
June 07, 2004

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 7, 2004**

EPIX Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other
jurisdiction of
incorporation)

000-21863
(Commission
File Number)

04-3030815
(IRS Employer
Identification No.)

71 Rogers Street
Cambridge, Massachusetts 02142

(Address of principal executive offices) (Zip Code)

Edgar Filing: EPIX MEDICAL INC - Form 8-K

Registrant's telephone number, including area code: **(617) 250-6000**

Item 5. Other Events.

On June 7, 2004, EPIX Medical, Inc. issued a press release announcing that MS-325, its new intravenous blood pool contrast agent for Magnetic Resonance Angiography (MRA), has been submitted for marketing approval in the European Union by its worldwide marketing partner, Schering AG, Germany. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 7. Financial Statements and Exhibits.

(c) The following exhibit is furnished with this report:

| Exhibit Number | Description |
|----------------|-----------------------------------|
| 99.1 | Press Release dated June 7, 2004. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX Medical, Inc.
(Registrant)

Date: June 7, 2004

/s/

Peyton J. Marshall
Peyton J. Marshall
*Senior Vice-President,
Finance and Administration,
Chief Financial Officer*